By targeting the IFN‐γ‐STAT1 axis, NGO suppresses M1‐mediated inflammation while simultaneously enhancing Treg induction, and reducing GVHD severity without compromising essential immune functions. This evidence concerns the gene IFNG and graft versus host disease.